Baricitinib, an oral selective JAK1/2 inhibitor, has regulatory approval for indications including rheumatoid arthritis (RA), alopecia areata, atopic dermatitis, and severe COVID-19 (4, 5). The gene discussed is JAK1; the disease is rheumatoid arthritis.